MEA Tumor Ablation Market - Industry Trends and Forecast to 2030

TABLE OF CONTENT

1 INTRODUCTION 35
1.1 OBJECTIVES OF THE STUDY 35
1.2 MARKET DEFINITION 35
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA TUMOR ABLATION MARKET 35
1.4 CURRENCY AND PRICING 37
1.5 LIMITATIONS 37
1.6 MARKETS COVERED 37
2 MARKET SEGMENTATION 40
2.1 MARKETS COVERED 40
2.2 GEOGRAPHICAL SCOPE 41
2.3 YEARS CONSIDERED FOR THE STUDY 42
2.4 Cognate Lifesciences TRIPOD DATA VALIDATION MODEL 43
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 46
2.6 MULTIVARIATE MODELLING 47
2.7 TYPE SEGMENT LIFELINE CURVE 48
2.8 MARKET END USERS COVERAGE GRID 49
2.9 Cognate Lifesciences MARKET POSITION GRID 50
2.10 VENDOR SHARE ANALYSIS 51
2.11 SECONDARY SOURCES 52
2.12 ASSUMPTIONS 52
3 EXECUTIVE SUMMARY 53
4 PREMIUM INSIGHTS 55
4.1 PESTEL ANALYSIS 56
4.2 PORTER'S FIVE FORCES MODEL 57
5 REGULATORY FRAMEWORK 58
5.1 REGULATORY SCENARIO IN SAUDI ARABIA 58
6 MARKET OVERVIEW 59
6.1 DRIVERS 61
6.1.1 RISING PREVALENCE OF CANCER MIDDLE EAST & AFRICALY 61
6.1.2 INCREASING INCLINATION OF SURGEONS AND PATIENTS TOWARD MINIMALLY INVASIVE PROCEDURES 61
6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS 62
6.1.4 INCREASING AWARENESS AND EDUCATION 62
6.2 RESTRAINTS 63
6.2.1 REGULATORY HURDLES FOR APPROVAL 63
6.2.2 LIMITED CLINICAL EVIDENCE 63
6.3 OPPORTUNITIES 64
6.3.1 FAVORABLE REIMBURSEMENT SCENARIO 64
6.3.2 STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 64
6.4 CHALLENGES 65
6.4.1 TECHNICAL CHALLENGES IN TARGETING THE TUMOR 65
6.4.2 COMPETITION FROM ALTERNATIVE TREATMENT MODALITIES 65
7 MIDDLE EAST & AFRICA TUMOR ABLATION MARKET, BY TYPE 66
7.1 OVERVIEW 67
7.2 THERMAL ABLATION 70
7.2.1 TUMOR ABLATION SYSTEMS 71
7.2.1.1 RADIOFREQUENCY 72
7.2.1.1.1 BIPOLAR 72
7.2.1.1.2 MULTIPOLAR 72
7.2.2 IMAGE GUIDANCE PRODUCTS AND ACCESSORIES 72
7.2.2.1 CT 73
7.2.2.2 MR IMAGING 73
7.2.2.3 FLUOROSCOPY 73
7.2.2.4 OTHERS 73
7.2.2.5 MICROWAVE 73
7.2.2.6 CRYOABLATION 73
7.2.2.7 HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU) 73
7.2.2.8 LASER 73
7.3 CHEMICAL ABLATION 73
7.3.1 ETHANOL 74
7.3.2 ACETIC ACID 74
8 MIDDLE EAST & AFRICA TUMOR ABLATION MARKET, BY TYPES OF TREATMENT 75
8.1 OVERVIEW 76
8.2 PERCUTANEOUS 79
8.2.1 BREAST CANCER 80
8.2.2 LUNG CANCER 80
8.2.3 PROSTATE CANCER 80
8.2.4 LIVER CANCER 80
8.2.5 KIDNEY CANCER 80
8.2.6 OTHER CANCERS 80 
8.3 LAPAROSCOPY 80
8.3.1 BREAST CANCER 81
8.3.2 LUNG CANCER 81
8.3.3 PROSTATE CANCER 81
8.3.4 LIVER CANCER 81
8.3.5 KIDNEY CANCER 82
8.3.6 OTHER CANCERS 82
8.4 SURGICAL 82
8.4.1 BREAST CANCER 83
8.4.2 LUNG CANCER 83
8.4.3 PROSTATE CANCER 83
8.4.4 LIVER CANCER 83
8.4.5 KIDNEY CANCER 83
8.4.6 OTHER CANCERS 83
9 MIDDLE EAST & AFRICA TUMOR ABLATION MARKET, BY CANCER TYPE 84
9.1 OVERVIEW 85
9.2 BREAST CANCER 88
9.3 LUNG CANCER 88
9.4 PROSTATE CANCER 89
9.5 LIVER CANCER 90
9.6 KIDNEY CANCER 91
9.7 BONE CANCER 92
9.8 OTHERS 93
10 MIDDLE EAST & AFRICA TUMOR ABLATION MARKET, BY END USERS 94
10.1 OVERVIEW 95
10.2 HOSPITALS 98
10.3 ONCOLOGY CENTERS 98
10.4 OTHERS 99
11 MIDDLE EAST & AFRICA TUMOR ABLATION MARKET, BY DISTRIBUTION CHANNEL 100
11.1 OVERVIEW 101
11.2 DIRECT TENDER 104
11.3 RETAIL SALES 104 
12 MIDDLE EAST & AFRICA TUMOR ABLATION MARKET, BY REGION 106
12.1 MIDDLE EAST AND AFRICA 107
12.1.1 SAUDI ARABIA 116
12.1.2 SOUTH AFRICA 121
12.1.3 U.A.E. 126
12.1.4 EGYPT 131
12.1.5 ISRAEL 136
12.1.6 REST OF MIDDLE EAST AND AFRICA 141
13 MIDDLE EAST & AFRICA TUMOR ABLATION MARKET, COMPANY LANDSCAPE 142
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 142
14 SWOT ANALYSIS 143
15 COMPANY PROFILE 144
15.1 BOSTON SCIENTIFIC CORPORATION 144
15.1.1 COMPANY SNAPSHOT 144
15.1.2 REVENUE ANALYSIS 144
15.1.3 COMPANY SHARE ANALYSIS 145
15.1.4 PRODUCT PORTFOLIO 145
15.1.5 RECENT DEVELOPMENT 145
15.2 MEDTRONIC 146
15.2.1 COMPANY SNAPSHOT 146
15.2.2 REVENUE ANALYSIS 146
15.2.3 COMPANY SHARE ANALYSIS 147
15.2.4 PRODUCT PORTFOLIO 147
15.2.5 RECENT DEVELOPMENT 147
15.3 OLYMPUS 148
15.3.1 COMPANY SNAPSHOT 148
15.3.2 REVENUE ANALYSIS 148
15.3.3 COMPANY SHARE ANALYSIS 149
15.3.4 PRODUCT PORTFOLIO 149
15.3.5 RECENT DEVELOPMENT 149
15.4 STRYKER 150
15.4.1 COMPANY SNAPSHOT 150
15.4.2 REVENUE ANALYSIS 150
15.4.3 COMPANY SHARE ANALYSIS 151
15.4.4 PRODUCT PORTFOLIO 151
15.4.5 RECENT DEVELOPMENT 151
15.5 BIOTRONIK 152
15.5.1 COMPANY SNAPSHOT 152
15.5.2 COMPANY SHARE ANALYSIS 152
15.5.3 PRODUCT PORTFOLIO 153
15.5.4 RECENT DEVELOPMENT 153
15.6 ANGIODYNAMICS. 154
15.6.1 COMPANY SNAPSHOT 154
15.6.2 REVENUE ANALYSIS 154
15.6.3 PRODUCT PORTFOLIO 155
15.6.4 RECENT DEVELOPMENT 155
15.7 BIOVENTUS LLC. 156
15.7.1 COMPANY SNAPSHOT 156
15.7.2 PRODUCT PORTFOLIO 156
15.7.3 RECENT DEVELOPMENT 156
15.8 BVM MEDICAL LIMITED 157
15.8.1 COMPANY SNAPSHOT 157
15.8.2 PRODUCT PORTFOLIO 157
15.8.3 RECENT DEVELOPMENT 157
15.9 EDAP TMS 158
15.9.1 COMPANY SNAPSHOT 158
15.9.2 REVENUE ANALYSIS 158
15.9.3 PRODUCT PORTFOLIO 159
15.9.4 RECENT DEVELOPMENT 159
15.10 ETHICON, INC. 160
15.10.1 COMPANY SNAPSHOT 160
15.10.2 PRODUCT PORTFOLIO 160
15.10.3 RECENT DEVELOPMENT 160
15.11 HEALTHTRONICS, INC. 161
15.11.1 COMPANY SNAPSHOT 161
15.11.2 PRODUCT PORTFOLIO 161
15.11.3 RECENT DEVELOPMENT 161
15.12 ICECURE MEDICAL 162
15.12.1 COMPANY SNAPSHOT 162
15.12.2 REVENUE ANALYSIS 162
15.12.3 PRODUCT PORTFOLIO 163
15.12.4 RECENT DEVELOPMENT 163
15.13 INSIGHTEC. 164
15.13.1 COMPANY SNAPSHOT 164
15.13.2 PRODUCT PORTFOLIO 164
15.13.3 RECENT DEVELOPMENT 164
15.14 INTEGRA LIFESCIENCES 165
15.14.1 COMPANY SNAPSHOT 165
15.14.2 REVENUE ANALYSIS 165
15.14.3 PRODUCT PORTFOLIO 166
15.14.4 RECENT DEVELOPMENT 166
15.15 MERIT MEDICAL SYSTEMS. 167
15.15.1 COMPANY SNAPSHOT 167
15.15.2 REVENUE ANALYSIS 167
15.15.3 PRODUCT PORTFOLIO 168
15.15.4 RECENT DEVELOPMENT 168
15.16 SONABLATE CORP. 169
15.16.1 COMPANY SNAPSHOT 169
15.16.2 PRODUCT PORTFOLIO 169
15.16.3 RECENT DEVELOPMENT 169
15.17 TERUMO EUROPE NV 170
15.17.1 COMPANY SNAPSHOT 170
15.17.2 PRODUCT PORTFOLIO 170
15.17.3 RECENT DEVELOPMENT 170
16 QUESTIONNAIRE 171
17 RELATED REPORTS 174